- Research Article
- 10.1016/j.nedt.2026.107044
Insights from an interprofessional education course- a mixed methods study among novice healthcare professionals.
- Jul 01, 2026
- Nurse education today
- Margalit Pade + 6 more +6
Publications from 2021 to 2026
Showing 10 of 23,108 papers
Insights from an interprofessional education course- a mixed methods study among novice healthcare professionals.
Response to: "From evidence to action: addressing the implementation gap in adolescent school start times".
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity-Matched Cohort Study.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score-matched study (Clalit Health Services, Israel, 2010-2023) comparing PCSK9 mAbs to ezetimibe. Adults prescribed PCSK9 mAbs for 6 months or more were matched 1:3 to ezetimibe-treated patients without prior cancer, applying a 1-year latency. The cohort included 9,876 patients (2,469 PCSK9 mAb; 7,407 ezetimibe; mean age 65). During a median 4.6-year follow-up, cancer occurred in 12% of PCSK9 mAb users and 11% of ezetimibe users (HR 1.09 [95% CI, 0.95-1.25]). In sex-stratified analysis, men on PCSK9 mAbs had a higher cancer incidence (12.5% vs. 10.3%, P = 0.03); no difference was observed in women. All-cause mortality was significantly lower in the PCSK9 mAb group (3% vs. 5%; HR 0.65 [95% CI, 0.54-0.80]). Post-cancer-diagnosis mortality did not differ. In this large cohort, PCSK9 mAb therapy appeared safe regarding overall cancer risk and was associated with a significant reduction in all-cause mortality; the slightly higher cancer incidence in men may likely be attributed to a higher prevalence of baseline risk factors.
Read moreEfficacy of energy-based devices on episiotomy pain and healing: A systematic review and meta-analysis.
Episiotomy is a common obstetric procedure often associated with significant postpartum pain and delayed wound healing. Conventional treatments provide limited relief and might not be suitable for all women. Energy-based therapies, including infrared irradiation and low-level laser therapy (LLLT), a non-thermal photo biomodulation technique, have shown potential for enhancing pain relief and tissue recovery, but their effectiveness in post-episiotomy care remains unclear. This study evaluates the efficacy of energy-based treatments on pain reduction and wound healing following episiotomy in postpartum women. A database search was performed using MEDLINE with Ovid and PubMed interfaces, The Cochrane Central Register of Controlled Trials (CENTRAL), Embase, ClinicalTrials.gov and Web of Science up to December 2024. Prospective randomized and non-randomized controlled trials were considered for inclusion. No restriction was imposed regarding the year or language of publication. Included studies compared one method of energy-based treatment to placebo, standard of care, no treatment or another intervention. Data were synthesized using RevMan Web (Version 8.14.0) with a random-effects model to account for interstudy heterogeneity. Pooled results were expressed as standardized mean differences (SMDs) with 95% confidence intervals. Evidence certainty was assessed using the GRADE approach. A total of 173 studies were identified through database searches, of which 13 studies were included in the final analysis, encompassing a total of 1377 patients. Analyses were stratified by intervention type: infrared irradiation versus standard care or no treatment (n = 1088), LLLT versus placebo (n = 209) and LLLT versus therapeutic ultrasound (n = 80). Infrared irradiation reduced postpartum pain compared to standard care or no treatment (SMD = -0.50, 95% confidence interval [CI]: -0.98 to -0.02, I2 = 88%, P < 0.01); however, it did not improve healing measures. LLLT showed no improvement in pain reduction (SMD: -0.31, 95% CI: -0.72 to 0.11, I2 = 53%, P = 0.1) or healing (SMD: 0.23, 95% CI: -0.18 to 0.63, I2 = 0%, P = 0.85) compared to placebo. LLLT compared to therapeutic ultrasound did not show advantage in pain or healing and was hindered by very high heterogeneity. Infrared therapy might reduce pain after episiotomy, although its effect on wound healing remains inconclusive. LLLT did not demonstrate significant benefits for pain relief or healing. CRD42024608543; registered December 2024.
Read moreAlanine scanning of the yeast killer toxin K2 reveals key residues for activity, gain-of-function variants, and supports prediction of precursor processing and 3D structure
• Mutational scanning indicates more processing sites in K2 than initially recognized. • Insights into precursor processing help to predict the mature toxin structure. • Single mutations can enhance killer toxin function and change target specificity. • Yeast killer toxins are part of structural families despite low sequence identity. Yeast killer toxins (YKTs) are antimicrobial proteins secreted by yeast with potential applications ranging from food preservation to therapeutic agents in human health. However, the practical use of many YKTs is limited by specific pH requirements, low temperature stability, low production yields, and narrow target specificity. While protein engineering could potentially overcome these challenges, progress is hindered by a lack of detailed knowledge about sequence-function relationships and structural data for these often multi-step processed proteins. In this study, we focused on the YKT K2, encoded by the M2 satellite dsRNA in Saccharomyces cerevisiae . Using alanine scanning mutagenesis of the full open reading frame and structure predictions combined with molecular dynamics simulations, we generated a comprehensive sequence-structure–function map, refined the model for the proteolytic processing of the K2 precursor, and predicted the mature toxin structure. Our findings also demonstrate that K2 can be engineered toward enhanced toxicity and altered target specificity through single-site mutations. Furthermore, we identified structural homology between K2 and other killer toxins, including the SMK toxin from the yeast Millerozyma farinosa . Our cost-effective workflow provides a platform to broadly map YKT sequence-structure–function relationships.
Read moreNonlinear quadrupole topological insulators
Prognostic implications of social anxiety comorbidity in major depressive disorder. Evidence from three large samples with adult and older patients.
Social anxiety disorder (SAD) frequently co-occurs with major depressive disorder (MDD). We examined the prevalence and clinical correlates of SAD across three heterogeneous MDD cohorts. Secondary analyses were conducted in adult (CO-MED: n=482; GSRD: n=1398) and late-life (IRL-GREY: n=438) patients. SAD was assessed dimensionally (PDSQ) and categorically (MINI; SCID-1). Cohort-specific instruments were used to assess depressive severity (QIDS; MADRS), suicidality (CHRT; MADRS; SIS) and hypomanic symptoms (ASRM; YMRS). In late-life depression, neurocognitive tests were administered. Multivariate models were adjusted for depression and anxiety levels. SAD prevalence varied markedly by samples and diagnostic definitions (CO-MED: 46.7% with PDSQ≥6; 17.0% with PDSQ>12; GSRD: 3.0%; IRL-GREY: 8.7%). Across cohorts, SAD was associated with earlier MDD onset (CO-MED: p<0.001 d=-0.36; GSRD: p=0.014 d=-0.39; IRL-GREY: p=0.002 d=-0.54) and greater anxiety comorbidity (CO-MED: GAD: p<0.001 d=1.24; panic: p<0.001 d=1.29; GSRD: GAD: p<0.001; panic: p<0.001; IRL-GREY: agoraphobia: p<0.001). After controlling for depression and anxiety levels, SAD was linked to higher suicide risk in both adult cohorts (CO-MED: OR 1.04 (1.01-1.08); GSRD: OR 1.29 (1.04-1.64)) and to lower 6-week remission in CO-MED cohort (OR 0.51 (0.29-0.91)). In MDD, SAD has consistent associations with earlier illness onset and anxiety burden, modest associations with suicidality and antidepressant outcomes, and reduced impact in late life.
Read moreLiver and Kidney volume Reduction May Underlie Metabolic Adaptation After Metabolic Bariatric Surgery: A sub-study of the "POWER" Randomized clinical trial.
Homogeneous boundary control for a 1D reaction–diffusion PDE: Modal decomposition approach
Clinical Outcomes Among Older Adults Hospitalized with Respiratory Syncytial Virus and Influenza Infection: A Retrospective Analysis.
Respiratory syncytial virus (RSV) is a major cause of morbidity and mortality among older adults. Limited information is available in Israel regarding RSV outcomes, particularly compared to influenza, to guide strategies for RSV vaccination. This study aimed to characterize RSV infection and predictors of clinical outcomes among hospitalized adults aged ≥ 60years in Israel between 2016 and 2023, and to compare disease severity and outcomes with those of seasonal influenza hospitalizations. A retrospective analysis was conducted of hospitalized adults aged ≥ 60years with positive RSV or influenza confirmed via standard-of-care RT-PCR between 2016 and 2023. The primary outcome was a composite of intensive care unit (ICU) admission, mechanical ventilation, vasopressor support, or 30-day mortality. Cardiovascular complications were recorded. An inverse probability treatment weighting (IPTW) was used to adjust for potential confounding. Weighted and unweighted relative risks (RRs) were estimated to compare clinical outcomes between RSV and influenza. Overall, 817 RSV-positive and 2113 influenza-positive patients were included. Among patients with RSV, 30-day and 90-day mortality rates were 11.9% and 18.8% respectively; ICU admission was required for 10.6%, mechanical ventilation for 6.4%, and vasopressor support for 6.5%. Tachyarrhythmia was documented in 17.7% and ischemia in 9.9%. Predictors of the composite primary outcome included chronic pulmonary disease, lower respiratory tract infection, hypothermia, elevated pulse, lower blood pressure and increased creatinine. In IPTW-adjusted analyses, RSV infection had a trend for increased risk for the composite primary outcome (RR 1.03, 95% confidence interval [CI] 1.00, 1.06) and 90-day mortality (RR 1.02, 95%CI 0.99, 1.05) compared with influenza. Among hospitalized older adults, RSV infection carries considerable morbidity and mortality and may have a higher risk for poor clinical outcomes compared with influenza. These findings support the prioritization of RSV vaccination programs among older adults.
Read more